Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2005121149) FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2005/121149 International Application No.: PCT/GB2005/002318
Publication Date: 22.12.2005 International Filing Date: 10.06.2005
IPC:
C07D 491/04 (2006.01) ,A61K 31/44 (2006.01) ,A61P 9/04 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
491
Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
04
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Applicants:
FORD, John [GB/GB]; GB (UsOnly)
PALMER, Nicholas, John [GB/GB]; GB (UsOnly)
ATHERALL, John, Frederick [GB/GB]; GB (UsOnly)
MADGE, David, John [GB/GB]; GB (UsOnly)
XENTION DISCOVERY LIMITED [GB/GB]; Pampisford Park London Road Pampisford Cambridge CB2 4EF, GB (AllExceptUS)
Inventors:
FORD, John; GB
PALMER, Nicholas, John; GB
ATHERALL, John, Frederick; GB
MADGE, David, John; GB
Agent:
CHAPMAN, Paul, William ; Kilburn & Strode 20 Red Lion Street London WC1R 4PJ, GB
Priority Data:
0412986.210.06.2004GB
60/578,35010.06.2004US
Title (EN) FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS
(FR) COMPOSES DE FURANOPYRIMIDINE EFFICACES COMME INHIBITEURS DES CANAUX POTASSIQUES
Abstract:
(EN) A compound of formula (I) wherein R1 is aryl, heteroaryl, cycloalkyl or alkyl; R2 is H, alkyl, nitro, -CO2R7, CONR4R5 or halo; R3 is H, NR4R5, NC(O)R8, halo, trifluoromethyl, alkyl, nitrile or alkoxy; R4 and R5 may be the same or different, and may be H, alkyl, aryl, heteroaryl or cycloalkyl; or R4 and R5 may together form a saturated, unsaturated or partially saturated 4 to 7 member ring, wherein said ring may optionally comprise one or more further heteroatoms selected from N, O or S; X is O, S or NR6; R6 is H or alkyl; R7 is hydrogen, methyl or ethyl; R8 is methyl or ethyl; Ll is (CH2)n, where n is 1,2 or 3; and Y is aryl, a heterocyclic group, alkyl, alkenyl or cycloalkyl; together with pharmaceutically acceptable salts thereof. The use of these compounds as potassium channel inhibitors is also described.
(FR) Cette invention concerne un composé représenté par la formule (I), dans laquelle R1 représente aryle, hétéroaryle, cycloalkyle ou alkyle ; R2 représente H, alkyle, nitro, -CO2R7, CONR4R5 ou halo ; R3 représente H, NR4R5, NC(O)R8, halo, trifluorométhyle, alkyle, nitrile ou alcoxy ; R4 et R5, qui peuvent être identiques ou différents, peuvent représenter H, alkyle, aryle, hétéroaryle ou cycloalkyle ; ou R4 et R5 peuvent former ensemble un cycle de 4 à 7 éléments saturé, insaturé ou partiellement saturé et pouvant éventuellement contenir un ou plusieurs autres hétéroatomes choisis parmi N, O ou S ; X représente O, S ou NR6 ; R6 représente H ou alkyle ; R7 représente hydrogène, méthyle ou éthyle ; R8 représente méthyle ou éthyle ; L représente (CH2)n, où n est égal à 1,2 ou 3 ; et Y représente aryle, un groupe hétérocyclique, alkyle, alcényle ou cycloalkyle ; ainsi que des sels de ces composés acceptables sur le plan pharmaceutique. L'utilisation de ces composés comme inhibiteurs des canaux potassiques est également décrite.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)